<?xml version='1.0' encoding='utf-8'?>
<document id="22721873"><sentence text="Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers."><entity charOffset="31-42" id="DDI-PubMed.22721873.s1.e0" text="telmisartan" /><entity charOffset="48-60" id="DDI-PubMed.22721873.s1.e1" text="s-amlodipine" /><pair ddi="false" e1="DDI-PubMed.22721873.s1.e0" e2="DDI-PubMed.22721873.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s1.e0" e2="DDI-PubMed.22721873.s1.e1" /></sentence><sentence text="Telmisartan belongs to a class of orally active angiotensin II receptor blockers (ARBs), and S-amlodipine is an enantiomer of amlodipine"><entity charOffset="0-11" id="DDI-PubMed.22721873.s2.e0" text="Telmisartan" /><entity charOffset="48-62" id="DDI-PubMed.22721873.s2.e1" text="angiotensin II" /><entity charOffset="93-105" id="DDI-PubMed.22721873.s2.e2" text="S-amlodipine" /><entity charOffset="126-136" id="DDI-PubMed.22721873.s2.e3" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.22721873.s2.e0" e2="DDI-PubMed.22721873.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s2.e0" e2="DDI-PubMed.22721873.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22721873.s2.e0" e2="DDI-PubMed.22721873.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22721873.s2.e0" e2="DDI-PubMed.22721873.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22721873.s2.e1" e2="DDI-PubMed.22721873.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22721873.s2.e1" e2="DDI-PubMed.22721873.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22721873.s2.e1" e2="DDI-PubMed.22721873.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22721873.s2.e2" e2="DDI-PubMed.22721873.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22721873.s2.e2" e2="DDI-PubMed.22721873.s2.e3" /></sentence><sentence text=" Amlodipine is a racemic mixture and the calcium channel blocking (CCB) effect is confined to S-amlodipine, whereas R-amlodipine has a 1000-fold lower activity and no racemization occurs in vivo in human plasma"><entity charOffset="1-11" id="DDI-PubMed.22721873.s3.e0" text="Amlodipine" /><entity charOffset="41-48" id="DDI-PubMed.22721873.s3.e1" text="calcium" /><entity charOffset="94-106" id="DDI-PubMed.22721873.s3.e2" text="S-amlodipine" /><entity charOffset="116-128" id="DDI-PubMed.22721873.s3.e3" text="R-amlodipine" /><pair ddi="false" e1="DDI-PubMed.22721873.s3.e0" e2="DDI-PubMed.22721873.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s3.e0" e2="DDI-PubMed.22721873.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22721873.s3.e0" e2="DDI-PubMed.22721873.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22721873.s3.e0" e2="DDI-PubMed.22721873.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22721873.s3.e1" e2="DDI-PubMed.22721873.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22721873.s3.e1" e2="DDI-PubMed.22721873.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22721873.s3.e1" e2="DDI-PubMed.22721873.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22721873.s3.e2" e2="DDI-PubMed.22721873.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22721873.s3.e2" e2="DDI-PubMed.22721873.s3.e3" /></sentence><sentence text=" Combination therapy of ARBs with CCBs provides advantages for blood pressure control and vascular protection over monotherapy" /><sentence text="" /><sentence text="To investigate the effects of coadministration of telmisartan and S-amlodipine on the steady-state pharmacokinetic properties of each drug as a drug-drug interaction study required before developing the fixed-dose combination agent"><entity charOffset="50-61" id="DDI-PubMed.22721873.s6.e0" text="telmisartan" /><entity charOffset="66-78" id="DDI-PubMed.22721873.s6.e1" text="S-amlodipine" /><pair ddi="false" e1="DDI-PubMed.22721873.s6.e0" e2="DDI-PubMed.22721873.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s6.e0" e2="DDI-PubMed.22721873.s6.e1" /></sentence><sentence text="" /><sentence text="This study comprised 2 separate parts, A and B; each was a multiple-dose, open-label, 2-sequence, 2-period, crossover study in healthy male Korean volunteers" /><sentence text=" In part A, volunteers were administered 80 mg of telmisartan, either alone or with 5 mg of S-amlodipine"><entity charOffset="50-61" id="DDI-PubMed.22721873.s9.e0" text="telmisartan" /><entity charOffset="92-104" id="DDI-PubMed.22721873.s9.e1" text="S-amlodipine" /><pair ddi="false" e1="DDI-PubMed.22721873.s9.e0" e2="DDI-PubMed.22721873.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s9.e0" e2="DDI-PubMed.22721873.s9.e1" /></sentence><sentence text=" In part B, volunteers were administered 5 mg of S-amlodipine, either alone or with 80 mg of telmisartan"><entity charOffset="49-61" id="DDI-PubMed.22721873.s10.e0" text="S-amlodipine" /><entity charOffset="93-104" id="DDI-PubMed.22721873.s10.e1" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.22721873.s10.e0" e2="DDI-PubMed.22721873.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s10.e0" e2="DDI-PubMed.22721873.s10.e1" /></sentence><sentence text=" Blood samples were taken on days 9 and 37, following the final dose of each treatment, and at 0 (predose), 0" /><sentence text="5, 1, 1" /><sentence text="5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours after administration in part A, and were taken at 0 (predose), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, and 24 hours after administration in part B" /><sentence text=" Plasma concentrations were determined using LC-MS/MS" /><sentence text=" The pharmacokinetic properties of each drug after coadministration of telmisartan and S-amlodipine were compared with those of each drug administered alone"><entity charOffset="71-82" id="DDI-PubMed.22721873.s15.e0" text="telmisartan" /><entity charOffset="87-99" id="DDI-PubMed.22721873.s15.e1" text="S-amlodipine" /><pair ddi="false" e1="DDI-PubMed.22721873.s15.e0" e2="DDI-PubMed.22721873.s15.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s15.e0" e2="DDI-PubMed.22721873.s15.e1" /></sentence><sentence text=" Tolerability was assessed using measurements of vital signs, clinical chemistry tests, and interviews" /><sentence text="" /><sentence text="Fifty-six volunteers were enrolled (32 in part A and 24 in part B), and all completed except 4 volunteers (3 withdrawn in part A and 1 withdrawn in part B)" /><sentence text=" The geometric mean ratios (GMRs) (90% CI) for the C(max,ss) and AUC(τ,ss) of telmisartan (with or without S-amlodipine) were 1"><entity charOffset="78-89" id="DDI-PubMed.22721873.s19.e0" text="telmisartan" /><entity charOffset="107-119" id="DDI-PubMed.22721873.s19.e1" text="S-amlodipine" /><pair ddi="false" e1="DDI-PubMed.22721873.s19.e0" e2="DDI-PubMed.22721873.s19.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s19.e0" e2="DDI-PubMed.22721873.s19.e1" /></sentence><sentence text="039 (0" /><sentence text="881-1" /><sentence text="226) and 1" /><sentence text="003 (0" /><sentence text="926-1" /><sentence text="087), respectively" /><sentence text=" The GMRs (90% CI) for C(max,ss) and AUC(τ,ss) of S-amlodipine (with or without telmisartan) were 0"><entity charOffset="50-62" id="DDI-PubMed.22721873.s26.e0" text="S-amlodipine" /><entity charOffset="80-91" id="DDI-PubMed.22721873.s26.e1" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.22721873.s26.e0" e2="DDI-PubMed.22721873.s26.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s26.e0" e2="DDI-PubMed.22721873.s26.e1" /></sentence><sentence text="973 (0" /><sentence text="880-1" /><sentence text="076) and 0" /><sentence text="987 (0" /><sentence text="897-1" /><sentence text="085)" /><sentence text=" Total 11 adverse events (AEs) were reported in 7 volunteers (21" /><sentence text="9%) in part A" /><sentence text=" A total of 9 AEs were reported in 6 volunteers (25" /><sentence text="0%) in part B" /><sentence text=" Statistical analysis confirmed that the 90% CIs for these pharmacokinetic parameters were within the commonly accepted bioequivalence range of 0" /><sentence text="8 to 1" /><sentence text="25, indicating that the extent of bioavailability of S-amlodipine was not affected by telmisartan"><entity charOffset="53-65" id="DDI-PubMed.22721873.s39.e0" text="S-amlodipine" /><entity charOffset="86-97" id="DDI-PubMed.22721873.s39.e1" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.22721873.s39.e0" e2="DDI-PubMed.22721873.s39.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s39.e0" e2="DDI-PubMed.22721873.s39.e1" /></sentence><sentence text=" The intensity of all AEs was considered to be mild, and there were no significant differences in the prevalences of AEs between the 2 formulations" /><sentence text="" /><sentence text="Following multiple-dose coadministration of high doses of telmisartan and S-amlodipine, the steady-state pharmacokinetic properties of telmisartan were not significantly affected, and telmisartan had no significant effect on the pharmacokinetic properties of S-amlodipine at steady state in these selected groups of healthy volunteers"><entity charOffset="58-69" id="DDI-PubMed.22721873.s42.e0" text="telmisartan" /><entity charOffset="74-86" id="DDI-PubMed.22721873.s42.e1" text="S-amlodipine" /><entity charOffset="135-146" id="DDI-PubMed.22721873.s42.e2" text="telmisartan" /><entity charOffset="184-195" id="DDI-PubMed.22721873.s42.e3" text="telmisartan" /><entity charOffset="259-271" id="DDI-PubMed.22721873.s42.e4" text="S-amlodipine" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e0" e2="DDI-PubMed.22721873.s42.e0" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e0" e2="DDI-PubMed.22721873.s42.e1" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e0" e2="DDI-PubMed.22721873.s42.e2" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e0" e2="DDI-PubMed.22721873.s42.e3" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e0" e2="DDI-PubMed.22721873.s42.e4" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e1" e2="DDI-PubMed.22721873.s42.e1" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e1" e2="DDI-PubMed.22721873.s42.e2" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e1" e2="DDI-PubMed.22721873.s42.e3" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e1" e2="DDI-PubMed.22721873.s42.e4" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e2" e2="DDI-PubMed.22721873.s42.e2" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e2" e2="DDI-PubMed.22721873.s42.e3" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e2" e2="DDI-PubMed.22721873.s42.e4" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e3" e2="DDI-PubMed.22721873.s42.e3" /><pair ddi="false" e1="DDI-PubMed.22721873.s42.e3" e2="DDI-PubMed.22721873.s42.e4" /></sentence><sentence text=" Both formulations were generally well-tolerated" /><sentence text="" /></document>